Company Overview and News


Add GSK
to your dashboard

Headline News

Theravance Shares Rise on Approval of Glaxo's COPD Therapy

2017-11-17 zacks
Theravance Biopharma, Inc.’s (TBPH - Free Report) shares rose almost 6.5% on Thursday following the approval of GlaxoSmithKline plc’s (GSK - Free Report) chronic obstructive pulmonary disease ("COPD") therapy, Trelegy Ellipta in Europe. Investors cheered the approval as Theravance has an economic interest on the royalties that Glaxo will pay to its partner Innoviva, Inc. (INVA - Free Report) on global sales of Trelegy Ellipta. (36-0)

Glaxo's Triple Therapy COPD Inhaler Gets Marketing Nod in EU

2017-11-17 zacks
GlaxoSmithKline plc (GSK - Free Report) and partner Innoviva, Inc. (INVA - Free Report) announced that their triple combination therapy was granted marketing authorization in the EU as maintenance therapy for the treatment of patients with chronic obstructive pulmonary disease (COPD). (36-0)

Slumping Earnings Visibility Make GlaxoSmithKline (GSK) a Sell

2017-11-17 investorplace
GlaxoSmithKline Plc (NYSE:GSK) is one of 132 companies within the Pharmaceuticals GICS industry group, which is in turn part of the 782 company GICS Health Care sector. GSK's market value is $86.3 billion which places it in the top decile in its industry group. The ranking for GSK by Portfolio Grader places it 88 among the 132 companies in this industry group, giving it a lower than average position; in the third quartile of the sector with a ranking of 511 among the 782 companies in the sector, and number 3,219 in the nearly 5,000 company Portfolio Grader universe. (3-0)

AstraZeneca's (AZN) Asthma Drug Benralizumab Approved by FDA

2017-11-15 zacks
AstraZeneca, plc (AZN - Free Report) announced that the FDA has granted approval to its asthma disease candidate, benralizumab. Benralizumab, approved as an add-on maintenance treatment for severe eosinophilic asthma in patients aged 12 years and older, will be marketed by the trade name of Fasenra. (237-0)

Glaxo And Pfizer Are Top 'Safer' Dividend Healthcare Gainers For November

2017-11-15 seekingalpha
GSK, the top "safer" dividend healthcare stock, with a 32.1% net gain was 3x Pfizer's 10.4% second-place effort, and 10x JNJ's eighth-place gains as per analyst targets. (97-0)

Healthcare Dogfight: GlaxoSmithKline Regains Top By Gains In November As O&M & Patterson Close-In

2017-11-14 seekingalpha
GSK regained top dog by net gains, while TEVJF led again by yield as calculated 11/13/17. (174-0)

Glaxo's Subcutaneous Formulation of Benlysta Approved in EU

2017-11-14 zacks
GlaxoSmithKline plc (GSK - Free Report) announced approval in EU for a new self-injectable subcutaneous ("SC") formulation of Benlysta for systemic lupus erythematosus ("SLE"). The subcutaneous formulation is already approved in the United States. (101-0)

Deleterious Earnings Momentum Drop GlaxoSmithKline (GSK) to Sell

2017-11-10 investorplace
GlaxoSmithKline Plc (NYSE:GSK) is a $88.4 billion in market value constituent of the Pharmaceuticals GICS industry group where The current Portfolio Grader ranking for GSK puts it 77 among the 133 companies in this industry group, giving it a below-average spot. GSK is ranked in the third quartile of the sector with a ranking of 499 among the 785 companies in the sector and number 3,205 in the 5000 company Portfolio Grader company universe. (3-0)

2 High Quality U.K. Dividend Stocks For Your Portfolio.

2017-11-10 seekingalpha
Investors can sign up for Bargain Hunter to receive my real time trades in these and other stocks. (69-0)

Pharma Stock Roundup: AstraZeneca's Q3 Earnings, Roche & Merck Drugs Get FDA Nod

2017-11-10 zacks
Earnings remained in focus this week with companies like AstraZeneca (AZN - Free Report) reporting third quarter results. Meanwhile, companies like Roche (RHHBY - Free Report) and Merck & Co., Inc. (MRK - Free Report) were in the news due to regulatory updates. Recap of the Week’s Most Important Stories Mixed Results from AstraZeneca: AstraZeneca’s third quarter results were mixed with the company missing on earnings but beating on revenues. (56-0)

UPDATE 1-UK Stocks-Factors to watch on Nov 10

2017-11-10 reuters
Nov 10 (Reuters) - Britain’s FTSE 100 index is seen opening 13 points higher at 7,497 on Friday, according to financial bookmakers, with futures up 0.11 percent ahead of the cash market open. (55-1)

Dynvax Reaches The Final Point On Its Journey: FDA Approval Achieved For Hepatitis B Vaccine

2017-11-10 seekingalpha
HEPLISAV-B was shown to be superior to ENGERIX-B in a late-stage study with over 6,000 patients. (42-1)

Dynavax's hepatitis B vaccine gets FDA nod on third try, shares up

2017-11-09 channelnewsasia
REUTERS: Dynavax Technologies Corp's hepatitis B vaccine won the U.S. Food and Drug Administration's approval on the third attempt and Chief Executive Eddie Gray told Reuters the company was open to, but not waiting for, a partner to market the drug. (42-0)

AstraZeneca Earnings: Dividend Commitment Costly - Bloomberg

2017-11-09 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world. (85-0)

More Movements At The Top Of GlaxoSmithKline

2017-11-09 seekingalpha
GlaxoSmithKline (NYSE:GSK) has been having more than its share of ups and downs over the last few years. In 2014, they moved a lot of assets out of oncology, as part of a general rearrangement into higher-volume lower-cost areas. That was a pretty bold move - give management credit for not being timid, at least - and there were plenty of out-and-out cutbacks as well (such as the closure of the RTP site). (3-0)